未知生产厂商
Metenkefalin is an investigational endogenous opioid being studied for the treatment of COVID-19.
Metenkefalin is an investigational endogenous opioid being studied for the treatment of COVID-19.
Metenkefalin is an agonist of µ and δ opioid receptors. It also causes immunostimulation at low doses and immunosuppression at higher doses. Metenkefalin can also inhibit the production of aldosterone, deoxycorticosterone, and corticosterone. Unfortunately, the mechanisms by which these effects occur have not been well described in the literature.
Metenkefalin is indicated in Bosnia for the treatment of relapsing-remitting multiple sclerosis.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
